Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, INSERM UMR 938, Paris, France.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Bone Marrow Transplant. 2021 Apr;56(4):917-927. doi: 10.1038/s41409-020-01135-3. Epub 2020 Nov 18.
Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of complications. Triggering event(s) of such complications vary significantly, but often a so-called "multi-organ failure" (MOF) is reported as the leading cause of death. The identification of the exact trigger of MOF is critical towards early and disease-specific intervention to improve outcome. We examined data from 202 alloHCT patients reported to have died of MOF from the EBMT registry aiming to determine their exact cause of death focusing on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) due to its life-threatening, often difficult to capture yet preventable nature. We identified a total of 70 patients (35%) for whom VOD/SOS could be considered as trigger for MOF and leading cause of death, among which 48 (69%) were previously undiagnosed. Multivariate analysis highlighted history of hepatic comorbidity or gentuzumab use and disease status beyond CR1 as the only significant factors predictive of VOD/SOS incidence (OR = 6.6; p = 0.001 and OR = 3.3; p = 0.004 respectively). VOD/SOS-related MOF was widely under-reported, accounting for 27% of deaths attributed to MOF of unknown origin without a previous VOD/SOS diagnosis. Our results suggest most missed cases developed late VOD/SOS beyond 21 days post-alloHCT, highlighting the importance of the newly revised EBMT criteria.
异基因造血细胞移植(alloHCT)是一种复杂的、可能致命的治疗方法,具有多种并发症。这些并发症的触发因素差异很大,但通常报告所谓的“多器官衰竭”(MOF)是导致死亡的主要原因。确定 MOF 的确切触发因素对于早期和针对特定疾病的干预以改善结果至关重要。我们检查了来自 EBMT 登记处的 202 名报告因 MOF 死亡的 alloHCT 患者的数据,旨在确定他们的确切死因,重点关注静脉阻塞性疾病/窦状阻塞综合征(VOD/SOS),因为它具有威胁生命、常常难以捕捉但可预防的性质。我们共确定了 70 名(35%)患者,可将 VOD/SOS 视为 MOF 的触发因素和主要死因,其中 48 名(69%)患者之前未被诊断。多变量分析突出了肝合并症或 gentuzumab 使用史以及 CR1 以外的疾病状态是预测 VOD/SOS 发生率的唯一显著因素(OR=6.6;p=0.001 和 OR=3.3;p=0.004)。VOD/SOS 相关的 MOF 广泛漏报,占归因于 MOF 的未知来源的死亡的 27%,而没有之前的 VOD/SOS 诊断。我们的结果表明,大多数漏诊病例在 alloHCT 后 21 天以上发生晚期 VOD/SOS,突出了新修订的 EBMT 标准的重要性。